Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Restructuring Costs (2021 - 2025)

Collegium Pharmaceutical has reported Restructuring Costs over the past 3 years, most recently at $10.9 million for Q3 2025.

  • Quarterly results put Restructuring Costs at $10.9 million for Q3 2025, up 39.88% from a year ago — trailing twelve months through Sep 2025 was $43.5 million (up 50.89% YoY), and the annual figure for FY2024 was $33.7 million, up 4.27%.
  • Restructuring Costs for Q3 2025 was $10.9 million at Collegium Pharmaceutical, up from $9.8 million in the prior quarter.
  • Over the last five years, Restructuring Costs for COLL hit a ceiling of $13.3 million in Q1 2025 and a floor of $4.6 million in Q4 2021.
  • Median Restructuring Costs over the past 3 years was $9.0 million (2024), compared with a mean of $9.0 million.
  • Peak annual rise in Restructuring Costs hit 54.11% in 2025, while the deepest fall reached 25.49% in 2025.
  • Collegium Pharmaceutical's Restructuring Costs stood at $4.6 million in 2021, then soared by 106.92% to $9.5 million in 2024, then grew by 15.12% to $10.9 million in 2025.
  • The last three reported values for Restructuring Costs were $10.9 million (Q3 2025), $9.8 million (Q2 2025), and $13.3 million (Q1 2025) per Business Quant data.